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At a glance commentary: 
Evidence associates the renin-angiotensin system in the control of skeletal muscle bulk and 
function, and suggests angiotensin II is implicated in the skeletal muscle dysfunction seen in 
 
 
individuals with COPD.  Thus manipulation of this pathway may allow greater response to 
exercise interventions such as pulmonary rehabilitation.  We report on the first placebo-
controlled, double-blind, randomised controlled trial to investigate if angiotensin-converting 
enzyme (ACE) inhibition, without a conventional existing clinical indication, could enhance 
the impacts of pulmonary rehabilitation on exercise capacity in patients with COPD.  
Contrary to expectation, ACE-inhibition mediated by enalapril administration actually 
attenuated the increase in exercise capacity resulting from pulmonary rehabilitation in 
COPD. 
 
 
"This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org".
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ABSTRACT 
Rationale: Epidemiological studies in older individuals have found an association between 
use of ACE-inhibition (ACE-I) therapy and preserved locomotor muscle mass, strength and 
walking speed. ACE-I therapy might therefore have a role in the context of pulmonary 
rehabilitation.   
Objectives: We investigated the hypothesis that enalapril, an ACE-inhibitor, would augment 
the improvement in exercise capacity seen during pulmonary rehabilitation. 
Methods: We performed a double-blind, placebo-controlled, parallel-group randomised 
controlled trial.  COPD patients, with at least moderate airflow obstruction and taking part 
in pulmonary rehabilitation, were randomised to either 10 weeks therapy with an ACE-
inhibitor (10mg enalapril) or placebo.   
Measurements: The primary outcome measurement was the change in peak power 
(assessed using cycle ergometry) from baseline. 
Main Results: Eighty patients were enrolled, seventy-eight randomised (age 67±8years, FEV1 
48±21% predicted), and sixty-five completed the trial (34 placebo, 31 ACE-inhibitor).  The 
ACE-inhibitor treated group demonstrated a significant reduction in systolic blood pressure 
(Δ-16mmHg, 95% CI -22 to -11) and serum ACE activity (Δ-18IU/L, 95% CI -23 to -12) versus 
placebo (between group differences p<0.0001).  Peak power increased significantly more in 
the placebo group (placebo Δ+9 Watts, 95% CI 5 to 13 vs. ACE-I Δ+1 Watt, 95% CI -2 to 4, 
between group difference 8 Watts, 95% CI 3 to 13, p=0.001).  There was no significant 
between group difference in quadriceps strength or health-related quality of life.   
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Conclusion:  Use of the ACE-inhibitor enalapril alongside a programme of pulmonary 
rehabilitation, in patients without an established indication for ACE-inhibition, reduced the 
response to exercise training in COPD patients. 
Word count: 244   
Key words: COPD, renin-angiotensin system, exercise, rehabilitation 
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INTRODUCTION 
Skeletal muscle dysfunction is a common and important extra-pulmonary complication of 
COPD, associated with reduced endurance exercise capacity (1), impaired healthcare status 
(2) and greater mortality (3).  Whilst pulmonary rehabilitation (PR) is a high value treatment 
modality (4-6), its effects begin to decline towards baseline at 12-18 months (7, 8) and some 
patients with skeletal muscle dysfunction may be responding sub-optimally to this 
intervention (9).  There is thus a need for adjunctive agents to ensure that patients gain the 
greatest response from rehabilitation programs and maintain this for as long as possible. 
 
As components of circulating and tissue renin-angiotensin systems, the enzyme angiotensin-
converting enzyme (ACE) plays a key role in the synthesis of angiotensin II and degradation 
of vasoactive kinins, most notably bradykinin.  Evidence suggests a role for chronic 
activation of the intramuscular renin-angiotensin system (RAS) in regulating skeletal muscle 
phenotype, contributing to the skeletal muscle dysfunction seen in COPD (10).  There are 
several potential levels of action of ACE-inhibition in promoting effective skeletal muscle 
function, including attenuation of the activity of angiotensin II which contributes to pro-
inflammatory pathways, impaired glucose handling and promotes skeletal muscle atrophy 
(10).  Bradykinin activity is also known to influence insulin sensitivity (11), protect against 
oxidative damage (12) and promote angiogenesis (10), all essential components of skeletal 
muscle function.    
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Epidemiological studies in older populations have shown ACE-inhibitor therapy to be 
associated with preserved locomotor muscle mass (13), leg strength (14) and walking speed 
(14) and thus could be predicted to affect exercise capacity, although these are 
observational findings and the exact mechanisms behind these associations have not been 
fully investigated.  In line with this, individuals with genetically low serum and tissue ACE 
levels, associated with a polymorphism of the human ACE gene, have improved exercise 
characteristics both healthy and athletic populations (15, 16) and improved mechanical 
efficiency in response to training (17).  Following this, COPD patients possessing the same 
genotype demonstrated greater peak workload during incremental cardiopulmonary 
exercise testing than those with higher intrinsic levels of ACE activity (18).  Observational 
work has also shown that the bradykinin receptor polymorphism leading to reduced activity 
at the bradykinin receptor (+9/+9 BK2R) to be associated with both reduced fat-free mass 
and quadriceps strength in COPD (19). 
 
In an elderly population with restricted mobility, ACE-inhibition was associated with an 
improvement in six minute walking distance (20).  Furthermore, in COPD patients 
pharmacological reduction in angiotensin II has been associated with improvements in both 
quadriceps strength (21) as well as exercise capacity as assessed by incremental 
cardiopulmonary exercise testing, with a 7% increase in peak workload achieved following 
four weeks therapy with enalapril in those with moderate to severe airflow obstruction (22).  
However, in another study in COPD patients stratified on the basis of quadriceps weakness 
(quadriceps maximal volitional contraction strength <120% BMI), the use of the ACE-
inhibitor fosinopril did not improve either quadriceps strength or endurance (23).  Animal 
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studies have, however, suggested a potential synergistic role for ACE-inhibition and exercise 
in ensuring a more favourable skeletal muscle phenotype to promote greater exercise 
capacity (24). This raises the possibility that a training stimulus may be required to ensure 
maximal benefit from reduced angiotensin II activity.   
 
Thus the aim of this study was to investigate the effects of therapy with an ACE-inhibitor as 
an adjunctive therapy to a standardised programme of pulmonary rehabilitation in a COPD 
population, with focus on the effects on exercise capacity, strength, health-related quality of 
life and daily physical activity. 
 
MATERIALS AND METHODS 
Patient Selection 
All participants provided written informed consent prior to enrolment in the study which 
was approved by the London Bloomsbury Research Ethics Committee (REC reference 
12/LO/0331) and registered prospectively on a publicly accessible database 
(www.controlled-trials.com/ISRCTN79038750).   
 
Stable COPD patients of GOLD stage II-IV (25) referred for pulmonary rehabilitation, and 
with an MRC dyspnoea score of at least 3, or 2 with functional limitation (26), were 
considered for inclusion.  Individuals already using ACE-inhibitors or angiotensin-receptor 
blockers or with other reason to benefit from these medicines (including ischaemic heart 
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disease, impairment of ventricular function and diabetes mellitus) were excluded from the 
study.  Other principle exclusion criteria were renovascular disease or significant renal 
impairment (defined as an eGFR <50ml/min/1.73m2), pulmonary exacerbation within one 
month, recent (less than 3 months) prior pulmonary rehabilitation course or other comorbid 
factors which either significantly impaired exercise capacity or ability to participate in 
rehabilitation, including significant musculoskeletal, neurological and aortic valve disease.  
Individuals with hypotension (defined as a systolic blood pressure less than 100mmHg) were 
excluded from participation. 
 
Study design  
 
The study was a double-blind, placebo-controlled, parallel-group randomised trial.  The 
primary outcome measure was the between group difference in the absolute change in 
peak power achieved on incremental cycle ergometry.  This measure is a validated endpoint 
in COPD and provides an effective evaluation of whole body exercise capacity, taking into 
consideration both cardiorespiratory and skeletal muscle function, having been used in large 
trials such as the National Emphysema Treatment Trial (NETT) study (27).  Leg fatigue has 
been shown to be more likely to limit cycle-based tasks than walking exercise (28).  Hence, 
cycle ergometry may be more discriminatory in the assessment of interventions that 
influence skeletal muscle function.  Both genotype based studies (18) and clinical research 
(22) have shown reduced angiotensin II activity to be associated with improved peak power 
achieved during incremental cardiopulmonary exercise testing in COPD.  Secondary 
outcome measures included the between group differences in the change in quadriceps 
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maximal volitional contraction force, health-related quality of life and daily physical activity 
level. 
 
Intervention and randomisation 
 
Patients were randomly allocated to receive either ACE-inhibitor (10mg enalapril once daily) 
or placebo (microcrystalline cellulose) for 10 weeks in a 1:1 manner using block 
randomisation and a block size of 4.  Randomisation was performed by Imperial College 
Trials Unit using a stratified approach, based on the baseline peak power achieved on 
incremental cycle ergometry (using 50 Watts as a cut-off) and ACE genotype (II, ID or DD; I 
representing the insertion allele and D the deletion allele; the I allele is associated with 
lower ACE activity (19, 29, 30)).  ACE genotype was assessed by polymerase chain reaction 
on DNA isolated from a saliva sample, the method for which is included in the online 
supplemental material.  Both subjects and the assessor were blind to treatment allocation. 
 
Study conduct 
 
Subjects were assessed at baseline and started enalapril/placebo treatment one week prior 
to the initiation of pulmonary rehabilitation.  The pulmonary rehabilitation programme was 
8 weeks in duration with a combination of educational and exercise sessions, incorporating 
both aerobic and strength training individualised to the patient as per national and 
international guidelines (4, 26).  The programme delivered 3 exercise sessions per week, 2 
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under direct supervision and 1 for the patient to undertake independently at home.  The 
sessions were delivered in a circuit style programme with a goal-setting and progressive 
approach.  Aerobic training included treadmill and cycle exercise, with individuals prescribed 
exercise at an intensity of 85% of their predicted VO2 peak.  Strengthening exercises 
included upper and lower limb resistive exercise with weights.  Blood pressure and renal 
function were checked one week after starting treatment and if symptomatically 
hypotensive (systolic blood pressure less than 100mmHg, or fall from baseline of greater 
than 10mmHg, with accompanying symptoms) or with evidence of significant decline in 
renal function (serum creatinine increase >30% beyond baseline) subjects were withdrawn 
from the study.   
 
Subjects reattended for assessment within one week of completion of the PR programme 
and continued therapy until completion of the study.  Patient assessments performed at 
baseline and following completion of rehabilitation included blood pressure, full pulmonary 
function, maximal symptom-limited incremental cycle ergometry, fat free mass assessed by 
bioelectrical impedance analysis, health-related quality of life assessment, quadriceps 
maximal volitional contraction, mid-thigh computed tomography scan and physical activity 
monitoring using a triaxial accelerometer.  Further details of these assessments are available 
in the on-line supplement.   
 
Data analysis and statistics 
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The primary endpoint selected in this study was peak workload achieved on incremental 
cycle ergometry.  Sample size was determined based on previous data showing an increase 
in peak power following rehabilitation, from 55±19 to 63±9 Watts (31).  To show an 
additional 10% improvement with ACE-inhibition, at an 80% statistical power with a 
significance level of 0.05, 54 individuals would need to complete the study.  Allowing for a 
10% withdrawal rate and individuals with genetically low ACE levels (II genotype, expected 
prevalence 25%) potentially responding to a lesser degree, led to a sample size of 80.  Data 
are presented as mean ± standard deviation or 95% confidence interval, and compared 
using two-sided paired (for comparison pre and post rehabilitation) or unpaired (comparing 
treatment groups) t-tests.  Categorical data are presented as percentages and comparisons 
performed using the Chi-squared test.  Analysis was performed on a per protocol basis using 
GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, California, USA).  
A p-value <0.05 was considered to be statistically significant. 
 
RESULTS 
Subjects 
80 patients were enrolled into the study, of whom 65 completed the full study protocol.  
There were five withdrawals in the placebo group and eight in the treatment group, further 
explanation of which is provided in the CONSORT diagram (figure 1). 
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Baseline characteristics 
The baseline characteristics of the group are presented in table 1.  The participants were 
representative of COPD subjects referred for pulmonary rehabilitation with a mean age 
67±8 years, FEV1 48±21% predicted, systolic blood pressure 137±18mmHg, MRC dyspnoea 
score 3±1, quadriceps strength 73±22% predicted and daily average step count of 
5428±3633.  79% of the subjects displayed evidence of ventilatory limitation at baseline (as 
assessed by the ratio of peak ventilation to the estimated maximal ventilation of ≥0.9 (32)).  
The groups were well-matched for age, gender, lung function and exercise capacity at 
baseline.  Although the difference in BMI reached statistical significance, it would not be 
considered to be a clinically important difference.  The ACE genotypes were consistent with 
Hardy-Weinberg equilibrium in both groups, and the distribution did not differ between the 
treatment arms. 
 
Effect of ACE-inhibition on blood pressure parameters  
In the placebo arm, systolic blood pressure was unchanged from baseline (Δ-1mmHg, 95% CI 
-5 to 4, p=0.78), whereas it was significantly reduced in the ACE-I arm (Δ-16mmHg, 95% CI -
22 to -11, p<0.0001) with a significant between group difference (-15mmHg, 95% CI -21 to -
9, p<0.0001) (figure 2).  Similar changes were also noted with diastolic blood pressure 
(placebo Δ+1mmHg, 95% CI -3 to 4, p=0.71 vs. ACE-I Δ-9mmHg, 95% CI -11 to -6, p<0.0001; 
between group difference -10mmHg, 95% CI -14 to -5, p=0.0001; figure 2). 
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Effect of ACE-inhibition on serum ACE levels 
There was a significant reduction in serum ACE levels in the ACE-I arm that was not seen in 
the placebo arm (placebo Δ+4IU/L, 95% CI 0 to 8, p=0.05 vs. ACE-I Δ-18IU/L, 95% CI -23 to -
12, p<0.0001; between group difference -22IU/L, 95% CI -29 to -15, p<0.0001; figure 3). 
 
Effect of ACE-inhibition on exercise capacity 
The peak power achieved on incremental cycle ergometry increased in both groups 
following pulmonary rehabilitation but the change was only significantly greater in the 
placebo group (placebo Δ+9 Watts, 95% CI 5 to 13, p<0.001 vs. ACE-I Δ+1 Watt, 95% CI -2 to 
4, p=0.62; between group difference 8 Watts, 95% CI 3 to 13, p=0.001; figure 4).  A similar 
pattern was seen in the change in peak pulmonary oxygen uptake (placebo 
Δ+1.37ml/min/kg, 95% CI 0.79 to 2.02, p=0.0001 vs. ACE-I Δ+0.33ml/min/kg, 95% CI -0.41 to 
1.08, p=0.45; between group difference 1.04ml/min/kg, 95% CI 0.08 to 2.01, p=0.035).   
 
There were no significant between group differences in the change in the VE/VCO2 slope 
from baseline to post pulmonary rehabilitation (placebo Δ-1.25, 95% CI -3.21 to 0.72, p=0.45 
vs. ACE-I Δ-0.87, 95% CI -2.17 to 0.43, p=0.18; between group difference 0.38, 95% CI -2.02 
to 2.78, p=0.57).  The oxygen uptake efficiency slope altered from baseline to post 
pulmonary rehabilitation more in the placebo group, although the between group 
difference failed to reach statistical significance (placebo Δ151, 96% CI 40 to 261, p=0.009 
vs. ACE-I Δ29, 95% CI -109 to 167, p= 0.67; between group difference 122, 95% CI -49 to 292, 
p=0.08). 
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Effect of ACE-inhibition on quality of life, lung function variables and strength  
Health-related quality of life scores, as assessed by the St. George’s Respiratory 
Questionnaire for COPD (SGRQ-C), improved in both treatment arms following pulmonary 
rehabilitation but there were no significant between group differences (table 2).  Lung 
function variables, measures of quadriceps strength and muscle bulk showed no significant 
between group differences (table 2).  Daily physical activity as assessed by the physical 
activity level (PAL) increased in the placebo arm but actually reduced in the treatment arm, 
producing a significant between group difference (table 2). 
 
Effect of ACE-inhibition on rate of adverse events, rehabilitation and drug compliance 
There was no difference in the rate of either pulmonary exacerbations or other adverse 
events comparing the study arms.  Although there was a statistically significant difference in 
the number of supervised rehabilitation sessions attended (placebo 13, 95% CI 12 to 14 vs. 
ACE-I 11, 95% CI 10 to 12; p=0.002), the actual difference was small and unlikely to have 
provided a more favourable training stimulus in the placebo group.  Drug compliance was 
excellent in both arms (placebo 96% compliance, 95% CI 93 to 98 vs. ACE-I 96% compliance, 
95% CI 94 to 99; p=0.45). 
 
Two patients in the ACE-inhibitor arm showed significant decline in renal function (>30% 
increase in serum creatinine) and were withdrawn from the study.  Only one patient, in the 
ACE-I treated arm, described a persistent cough, outside the context of a pulmonary 
exacerbation, but this did not lead to cessation of therapy. 
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DISCUSSION 
The main finding of this study was that enalapril, rather than enhancing the improvement in 
maximal exercise capacity seen with pulmonary rehabilitation in COPD, in fact reduced it.  
Enalapril did lower both blood pressure and serum ACE activity, confirming that a 
biologically relevant dose had been administered.  The current data therefore do not 
support the use of ACE-inhibitors to help ameliorate the skeletal muscle dysfunction in 
COPD when assessed through incremental cardiopulmonary exercise testing, and indeed 
suggest caution should be applied in this context. Clinically it is important to note that this 
conclusion applies only to individuals who do not have a clinically established reason for 
being on an ACE-I. 
 
Significance of the findings 
Studies of molecular pathways have suggested that the renin-angiotensin system is an 
important component of the skeletal muscle dysfunction seen in COPD (10), and previous 
experimental work has suggested a potential beneficial effect from ACE-inhibition on 
skeletal muscle phenotype so the results of the current study were unexpected.  This is, 
however, the first randomised controlled trial of ACE-inhibition as an adjunct to pulmonary 
rehabilitation.  Our findings emphasise the important role of prospective blinded 
randomised trials particularly as much previous work on both epidemiological cohorts (13, 
14) and ACE genotype polymorphisms (15, 18) suggesting ACE-inhibition might have 
beneficial effects was observational in nature.   
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Previous randomised controlled trials had suggested that manipulation of the RAS would 
produce favourable effects on exercise capacity in COPD subjects.  Andreas et al. showed 
that use of the angiotensin receptor blocker irbesartan for four months in severe COPD led 
to numerical improvements in quadriceps strength (21), and a small pilot study using 
enalapril for four weeks in 21 moderate to severe COPD subjects improved peak power 
achieved on incremental cycle ergometry (22).  However, our own group studied the 
administration of the ACE-inhibitor fosinopril to a group of moderate to severe COPD 
patients selected for quadriceps weakness, showing no improvement in either quadriceps 
strength, endurance or functional outcomes as measured by the incremental shuttle walk 
test (33).  In fact, despite exercise training not being administered in that study, an increase 
in quadriceps maximal volitional force of contraction (QMVC) was seen in both groups, but 
to a lesser extent in the ACE-inhibitor treated group than the placebo group, consistent with 
the current findings.  Recognised limitations of that study included the failure to stratify by 
ACE genotype and lack of a training stimulus, both issues that were addressed in this 
present study. 
 
We specifically excluded subjects with ischaemic heart disease, ventricular failure and 
diabetes, and thus although we cannot support use of ACE-inhibitors for targeting skeletal 
muscle dysfunction in COPD, many such patients will have other indications for ACE-
inhibitor therapy.  In fact it is well recognised that cardiovascular comorbidities are of a 
higher prevalence in COPD (34), and we would not support avoidance or cessation of ACE-
inhibitors when comorbidities known to benefit from such therapy are present. 
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Possible mechanism of action of ACE-inhibitors 
Despite epidemiological evidence suggesting ACE-inhibition should improve skeletal muscle 
function, the molecular basis for this remains unclear although several mechanisms have 
been proposed, including improved glucose sensitivity, promotion of hypertrophic 
pathways, reduction in local inflammation and enhancement of the effects of bradykinin  
(10).  There are several possible mechanisms by which ACE-inhibition may have attenuated 
the acute response to pulmonary rehabilitation, although the exact basis for the attenuation 
of gain in maximal exercise capacity in the current study remains unclear.  It could be 
hypothesised that reductions in total peripheral vascular resistance may divert blood flow 
away from actively exercising muscle and reduce perfusion pressure to the muscle vascular 
bed, impeding effective matching of blood flow to metabolic demand, although evidence 
suggests that, at least in the resting state, ACE-inhibition improves skeletal muscle blood 
flow by reducing vascular resistance (35, 36).   
 
Interestingly there is increasing evidence that tissue capillarity is reduced in COPD and 
associated with muscle contractile fatigue (37), and that increased capillarity is one 
mechanism through which rehabilitation is beneficial (9).  The RAS is implicated in 
angiogenesis and reactivity of the microvasculature of the skeletal muscle, with the 
administration of captopril in a rat model associated with reduced arteriolar density, 
diameter (38) and response to vasodilator stimuli (39), associated with reduced exercise 
tolerance (40).  The RAS is a complicated pathway and angiotensin (1-7), itself a breakdown 
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product of angiotensin II, is known to have muscle anti-atrophic effects (41), thus it is 
possible that ACE-inhibition is having several counter-regulatory effects. 
 
Although angiotensin II is recognised to have adverse effects on skeletal muscle, as with 
cardiac muscle, angiotensin II is important for tetanic strength and hypertrophy in response 
to mechanical loading (42).  It is recognised that COPD subjects with high intrinsic levels of 
angiotensin II (ACE DD genotype) have maintained strength (29).  In addition, peripheral 
muscle strength is known to be an important contributor to endurance capacity in COPD 
patients attending pulmonary rehabilitation (1), and it may be that by reducing angiotensin 
II activity we attenuated strength capacity, which in turn affected exercise performance.  
Thus it may be that the impact of high angiotensin II levels on strength and hypertrophy 
outweighs the impact of lower levels on exercise capacity in this context.   
 
It was interesting to note the reduced physical activity of those treated with ACE-inhibition 
in comparison to the rise seen in response to training in the placebo group.  Although it 
might be possible to speculate this was because of hypotension, in fact only two subjects in 
the ACE-inhibitor group reported symptomatic dizziness but this was transient, settled 
spontaneously and did not require cessation of therapy.  In addition, the change in symptom 
scores was comparable between treatment arms, suggesting the ACE-inhibitor treated 
group did not subjectively feel worse.  It is difficult to comment further on why this effect 
was seen, although the quality of life questionnaires employed understandably focussed on 
respiratory disability and may have not detected other relevant symptoms, although 
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patients in the treatment group did not report adverse effects that would explain the 
differences noted.   
 
Methodological issues 
This study was prospectively stratified by ACE genotype which is important as previous work 
has shown a greater response to exercise training in the II ACE genotype group (43).  A 
strong primary endpoint was selected and the groups were well-matched at baseline, 
lending confidence to the findings. 
 
We chose to use an ACE-inhibitor to ensure effects on both angiotensin II and bradykinin 
activity. Bradykinin receptor polymorphisms have been shown to impact on skeletal muscle 
phenotype in COPD (19, 30), and previous experimental work has shown bradykinin to have 
positive effects on skeletal muscle metabolism, including through the generation of nitric 
oxide, reduced oxidative stress and improved skeletal muscle insulin sensitivity (11, 12).  
Thus we chose an agent that would not only reduce angiotensin II activity but also enhance 
bradykinin activity.  Previous beneficial effects in COPD have been shown in trials with 
perindopril (20) and enalapril (22), although not with fosinopril (33).  Given that enalapril 
has previously been noted to improve peak work rate in COPD subjects (22), which was our 
selected primary outcome measure, this seemed an appropriate agent to select.  There was 
physiological evidence of adequate dosing, manifest by reduced blood pressure and serum 
ACE activity, although it is impossible to determine the effects on the skeletal muscle RAS 
without direct sampling.  This study does not exclude the possibility that the same effects 
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would be seen with all ACE-inhibitors but is in line with our previous work (33), suggesting 
this is likely a class effect.  It also remains unclear the time period over which ACE-inhibitors 
should be administered to influence the skeletal muscle phenotype, although shorter 
periods of treatment than we provided in this study have been associated with changes in 
exercise capacity (22). 
 
Potential study Limitations 
There are several possible limitations of the current study that deserve further mention.  
The enalapril treated group attended a lower number of physiotherapist led training 
sessions than the placebo treated group.  Whilst we believe this is unlikely to have been 
sufficient to account for the differences seen in outcomes, it is possible that this assumption 
is incorrect.  It is also possible that beneficial effects might have been noted had different 
exercise tests, such as endurance capacity during constant rate submaximal exercise, been 
used and this cannot be resolved without further study.   
 
It is also possible that certain subgroups of COPD patients may experience benefit from ACE-
inhibition whereas others may experience detrimental effects.  The current study was not 
sufficiently powered to allow effective subgroup analysis beyond the chosen stratification 
variables, and we cannot therefore address thisn point..  We recognise that we used quality 
of life questionnaires that focussed on respiratory disability.  While this was appropriate 
given the nature of the study, and different questionnaires might have been more effective 
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at detecting symptomatic changes induced by ACE-inhibition that could have influenced 
physical activity levels and exercise capacity.   
 
 
Conclusion 
Our results suggest that ACE-inhibition actually reduced the response to exercise training 
compared to placebo in patients with COPD, and thus ACE-inhibitors cannot be 
recommended for this indication. The biological mechanisms underlying this unexpected 
finding may warrant further scrutiny. We caution that our study specifically excluded 
patients with an established indication for ACE inhibition and therefore our data do not 
support withdrawing ACE inhibition from such patients during PR. 
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FIGURE LEGENDS 
Figure 1: CONSORT recruitment diagram for enrolment and study completion.  
Abbreviations: ACE-I - angiotensin-converting enzyme; A2RB – angiotensin II receptor 
blocker; GOLD – global initiative for chronic obstructive lung disease; PR – pulmonary 
rehabilitation. 
 
Figure 2: Alterations in blood pressure parameters (systolic blood pressure sBP and diastolic 
blood pressure dBP) from baseline to post pulmonary rehabilitation in the placebo (PL) and 
ACE-inhibitor (ACE-I) treatment arms.  Comparisons were made using unpaired t-tests, *p 
value <0.0001; †p value=0.0001. 
 
Figure 3: Change in serum ACE levels from baseline to post pulmonary rehabilitation in the 
placebo (PL) and ACE-inhibitor (ACE-I) treatment arms.  Comparison was made using an 
unpaired t-test, *p<0.0001. 
 
Figure 4: Change in peak workload achieved during incremental cycle ergometry from 
baseline to post pulmonary rehabilitation in the placebo (PL) and ACE-inhibitor (ACE-I) 
treatment arms.  Comparison was made using an unpaired t-test, *p =0.001. 
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TABLES 
 
Table 1: Demographic and baseline clinical characteristics of the subjects.   
 Placebo group (n=34) ACE-I group (n=31) p value 
Sex (% female) 41 55 0.27 
Age (years) 68 (7) 66 (10) 0.28 
ACE genotype (II, ID, DD) % 21, 47, 32 23, 42, 35 0.92 
BMI (kg/m2) 26.9 (5.9) 24.0 (4.6) 0.033* 
Systolic BP (mm Hg) 139 (17) 133 (15) 0.10 
Diastolic BP (mm Hg) 79 (11) 78 (9) 0.73 
LAMA (%) 71 84 0.20 
LABA-ICS (%) 79 71 0.43 
MRC dyspnoea score 3 (1) 3 (1) 0.52 
CAT score 18 (7) 17 (7) 0.65 
SGRQ-C total 46.25 (18.59) 46.78 (17.68) 0.91 
Average daily step count† 4883 (2668) 6685 (4234) 0.15 
Average PAL† 1.39 (0.20) 1.49 (0.19) 0.10 
FEV1 (L) 1.31 (0.53) 1.10 (0.54) 0.12 
FEV
1 
% predicted 51.6 (20.2) 48.2 (22.5) 0.37 
FVC (L) 3.25 (0.67) 2.96 (0.88) 0.15 
TLCO
c
 % predicted 54.2 (22.7) 51.1 (23.1) 0.59 
RV/TLC ratio (%) 52.8 (8.5) 56.5 (9.0) 0.09 
PaO
2
 (kPa) 10.4 (1.6) 10.4 (1.6) 0.87 
PaCO2 (kPa) 4.7 (0.6) 4.9 (0.6) 0.22 
Peak power on cycle (watts) 51 (22) 54 (29) 0.62 
Peak VO
2
 (ml/min/kg) 14.1 (3.1) 16.1 (5.4) 0.19 
VE/VCO2 slope 31.26 (7.84) 30.16 (7.59) 0.38 
OUES 1686 (485) 1658 (520) 0.73 
FFMI (kg/m2) 17.1 (2.3) 15.7 (1.8) 0.0089* 
QMVC (kg) 30.4 (11.0) 28.9 (10.1) 0.58 
MTMCSA (mm2) 9969 (2012) 9120 (2417) 0.12 
Quadriceps CSA (mm2) 4348 (950) 4027 (1277) 0.27 
 
Data shown are mean (SD).  Abbreviations: ACE – angiotensin converting enzyme; I – 
insertion allele; D – deletion allele; BMI – body mass index; BP – blood pressure; LAMA – 
long-acting muscarinic antagonist; LABA-ICS – long-acting beta-agonist and inhaled 
corticosteroid; MRC – Medical Research Council; CAT – COPD assessment test; SGRQ-C – St. 
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George’s respiratory questionnaire for COPD; PAL - physical activity level; FEV1 – forced 
expiratory volume in 1 second; FVC – forced vital capacity; TLCOc – carbon monoxide 
diffusion capacity; RV – residual volume; TLC – total lung capacity; PaO2 – arterial partial 
pressure of oxygen; PaCO2 – arterial partial pressure of carbon dioxide; VO2 – pulmonary 
oxygen uptake; VE – minute ventilation; VCO2 – pulmonary carbon dioxide production; 
OUES – oxygen uptake efficiency slope; FFMI – fat free mass index; QMVC – quadriceps 
maximal volitional contraction; MTMCSA -  mid-thigh muscle cross-sectional area. 
*p<0.05; †Data is analysed from 53 subjects (29 placebo, 24 treatment arm) who recorded 
an adequate period for physical activity assessment. 
 
Table 2: Change in outcome measures from baseline to post pulmonary rehabilitation. 
 Placebo group (n=34) ACE-I group (n=31) p value 
ΔCAT score -1 (3) 1 (4) 0.05 
ΔSGRQ-C Symptoms -0.55 (12.48) -3.00 (11.43) 0.56 
ΔSGRQ-C Activity -6.51 (13.30) -9.03 (15.65) 0.49 
ΔSGRQ-C Impacts -1.83 (7.82) -2.62 (10.63) 0.52 
ΔSGRQ-C Total -3.14 (6.10) -4.66 (8.71) 0.42 
ΔFEV1 (L) -0.02 (0.10) -0.01 (0.13) 0.91 
ΔFEV
1 
% predicted 0.02 (3.77) -0.10 (6.68) 0.93 
ΔTLCO
c
 % predicted -1.45 (4.82) -1.96 (5.61) 0.70 
ΔRV/TLC ratio (%) 0.39 (2.67) 0.09 (3.65) 0.70 
ΔPaO
2
 (kPa) -0.02 (1.16) 0.00 (1.12) 0.95 
ΔPaCO2 (kPa) 0.08 (0.38) 0.02 (0.41) 0.60 
ΔFFMI (kg/m2) -0.31 (0.87) -0.18 (0.54) 0.58 
ΔQMVC (kg) 2.09 (4.70) 0.37 (5.29) 0.17 
ΔMTMCSA (mm2) 53 (498) -52 (601) 0.45 
ΔQuadriceps CSA 
(mm2) 
81 (284) 69 (223) 0.86 
ΔDaily step count† 561 (2528) -382 (2082) 0.30 
ΔPAL† 0.04 (0.15) -0.06 (0.16) 0.030* 
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Data shown are mean (SD).  Abbreviations: ACE-I -  ACE-inhibitor; CAT – COPD assessment 
test; SGRQ-C – St. George’s respiratory questionnaire for COPD; FEV1 – forced expiratory 
volume in 1 second; TLCOc – carbon monoxide diffusing capacity; RV – residual volume; TLC 
– total lung capacity; PaO2 – arterial partial pressure of oxygen; PaCO2 – arterial partial 
pressure of carbon dioxide; FFMI – fat free mass index; QMVC – quadriceps maximal 
volitional contraction; MTMCSA -  mid-thigh muscle cross-sectional area; PAL - physical 
activity level. 
*p<0.05; †Data is analysed from 40 subjects (22 placebo, 18 treatment arm) who recorded 
an adequate period for physical activity assessment both at baseline and following 
rehabilitation. 
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